Adial Pharmaceuticals CEO Bill Stilley is leading the development of a genetically targeted therapeutic agent for alcohol use disorder. Adial is currently completing a Phase III trial to determine whether this oral medication can reduce overall alcohol use and the number of heavy drinking days.
As of March 2025 HealthBiz is part of CareTalk. Healthcare. Unfiltered and can be found at the following links:
Host David E. Williams is president of healthcare strategy consulting firm Health Business Group.
Episodes through March 2025 were produced by Dafna Williams.
